This licensing deal adds a preclinical IL-31R program to Apogee's pipeline, but no financial results or near-term catalysts are provided. Monitor for future IND filings and Phase I initiation, which would trigger the first $5.25M milestone. The deal structure is standard for early-stage biotech licensing and does not change the near-term outlook.
APGE drugs
APGE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 22 $132.55entry
- T+1 · 5mo ago +0.25%α +1.70% · $132.88
- T+5 · 5mo ago +0.05%α +0.50% · $132.61
- T+20 · 4mo ago +1.09%α +1.24% · $134.00
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics entered into an exclusive worldwide license agreement with Paragon Therapeutics for antibodies targeting IL-31R, a novel pipeline asset. The deal includes up to $23.25 million in development and regulatory milestones plus low-single-digit royalties on net sales. This expands Apogee's pipeline into a new target for inflammatory diseases but remains at the preclinical stage with no near-term catalysts.
Key Financial Metrics
Key Facts
- Exclusive worldwide license from Paragon for IL-31R-directed antibodies
- Up to $23.25 million in milestone payments: $5.25M (Phase I), $3M (Phase II), $5M (Phase III), $10M (FDA approval)
- Low-single-digit royalty on net sales of licensed products
- Optional CMC activities with fees ranging from $1.3M to $2.0M
- Paragon retains non-exclusive rights to develop multispecific antibodies targeting IL-31R
- Apogee is solely responsible for all development, manufacturing, and commercialization costs
Financial Impact
Up to $23.25 million in milestone payments plus low-single-digit royalties; optional CMC fees of $1.3M–$2.0M
Risk Factors
- Preclinical stage: no guarantee of clinical success or regulatory approval
- Milestone and royalty obligations create future cash outflows without guaranteed returns
- Paragon retains rights to multispecific antibodies that could compete with Apogee's monospecific products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-025841 |
| Document: ef20076542_ex10-1.htm | 0001140361-26-025841 |
| Document: ef20076542_8k.htm | 0001140361-26-025841 |
| Document: 0001140361-26-025841-index-headers.html | 0001140361-26-025841 |
| Document: 0001140361-26-025841-index.html | 0001140361-26-025841 |
| Document: 0001140361-26-025841.txt | 0001140361-26-025841 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers